Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart drug UDP-003 enters first human safety tests

NCT ID NCT06813339

Recruiting now Disease control Sponsor: Cyclarity Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-stage trial tests whether an experimental drug called UDP-003 is safe in healthy volunteers and people with heart disease. Researchers will give single or multiple doses of the drug or a placebo and monitor for side effects. The study includes 84 participants and is the first time UDP-003 is tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
UDP-003 (an experimental drug given by IV injection)
What this could lead to
If safe and effective, UDP-003 could become a new treatment to control atherosclerotic cardiovascular disease and reduce heart attack risk.
What could go wrong
This is a very early (Phase 1) trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results in healthy people may not apply to patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute subendocardial myocardial infarction atherosclerosis atherosclerotic cardiovascular disease intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROMES ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • CMAX Clinical Research

    RECRUITING

    Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.